ATE425460T1 - Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs - Google Patents

Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs

Info

Publication number
ATE425460T1
ATE425460T1 AT01972118T AT01972118T ATE425460T1 AT E425460 T1 ATE425460 T1 AT E425460T1 AT 01972118 T AT01972118 T AT 01972118T AT 01972118 T AT01972118 T AT 01972118T AT E425460 T1 ATE425460 T1 AT E425460T1
Authority
AT
Austria
Prior art keywords
pca
patients
psa
antibody
chain
Prior art date
Application number
AT01972118T
Other languages
English (en)
Inventor
Kim Pettersson
Hans Lilja
Timo Loevgren
Pauliina Niemelae
Original Assignee
Arctic Partners Oy Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arctic Partners Oy Ab filed Critical Arctic Partners Oy Ab
Application granted granted Critical
Publication of ATE425460T1 publication Critical patent/ATE425460T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01972118T 2000-09-27 2001-09-26 Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs ATE425460T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20002127A FI20002127A0 (fi) 2000-09-27 2000-09-27 Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi

Publications (1)

Publication Number Publication Date
ATE425460T1 true ATE425460T1 (de) 2009-03-15

Family

ID=8559172

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01972118T ATE425460T1 (de) 2000-09-27 2001-09-26 Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs

Country Status (9)

Country Link
US (1) US7872104B2 (de)
EP (1) EP1320756B1 (de)
JP (1) JP5254517B2 (de)
AT (1) ATE425460T1 (de)
AU (1) AU2001291911A1 (de)
DE (1) DE60137949D1 (de)
ES (1) ES2322432T3 (de)
FI (1) FI20002127A0 (de)
WO (1) WO2002027323A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5305361B2 (ja) 2007-05-04 2013-10-02 オプコ・ダイアグノスティクス・リミテッド・ライアビリティ・カンパニー 流体コネクタおよびマイクロ流体システム
DK2391451T3 (en) 2009-02-02 2018-10-15 Opko Diagnostics Llc STRUCTURES FOR MANAGING LIGHT INTERACTION WITH MICROFLUIDIC DEVICES
WO2013063312A1 (en) * 2011-10-25 2013-05-02 Memorial Sloan-Kettering Cancer Center Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer
WO2013061083A2 (en) 2011-10-28 2013-05-02 Fredax Ab Therapeutic agents and uses thereof
MY193914A (en) 2012-03-05 2022-11-01 Oy Arctic Partners Ab Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
US9575053B2 (en) 2012-03-30 2017-02-21 Kyoto University Urinary biomarker for use in test for prostate cancer
SMT201900338T1 (it) 2013-11-19 2019-07-11 Fredax Ab Anticopri anti-callicreina-2 umanizzato
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
DK3123381T3 (da) * 2014-03-28 2023-11-27 Opko Diagnostics Llc Sammensætninger og fremgangsmåder relateret til diagnose af prostatacancer
WO2016160545A1 (en) 2015-03-27 2016-10-06 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
CN107530412A (zh) * 2015-04-29 2018-01-02 欧普科诊断有限责任公司 用于主动监控前列腺癌的组合物和方法
CN108136013B (zh) * 2015-10-05 2023-04-18 弗雷达克斯有限责任公司 抗体多肽及其用途
CN109991405B (zh) * 2017-12-29 2023-01-24 上海索昕生物科技有限公司 一种免疫检测试剂盒及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0635575A1 (de) * 1993-07-22 1995-01-25 Wallac Oy Monoklonale Antikörper gegen Epitope in freiem uber nicht in Alpha-1-antichymotrypsin komplexiertem Prostata spezifisches Antigen
US6143509A (en) * 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
JPH10150999A (ja) * 1996-11-22 1998-06-09 Eiken Chem Co Ltd ヒト前立腺特異抗原−α１−アンチキモトリプシン複合体に対するモノクローナル抗体及びそれを用いたヒト前立腺特異抗原−α１−アンチキモトリプシン複合体の免疫学的検出法
US5858685A (en) * 1997-03-21 1999-01-12 The Board Of Trustees Of The Leland Stanford Junior University Prostate specific antigen from benign prostatic hyperplasia and its use in diagnosis
CA2286090C (en) * 1997-04-30 2013-01-08 Hybritech Incorporated Forms of prostate specific antigen and methods for their detection
US7659073B2 (en) * 1997-04-30 2010-02-09 Hybritech Incorporated Forms of prostate specific antigens and methods for their detection
US6482599B1 (en) 1999-04-30 2002-11-19 Hybritech Incorporated Forms of prostate specific antigen (PSA) specific for benign prostatic hyperplasia (BPH) and methods of using such
US7211397B2 (en) * 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6423503B1 (en) * 1999-04-30 2002-07-23 Hybritech Incorporated Forms of free prostate-specific antigen (PSA) and their association with prostate tissues from prostate peripheral zone and transition zone

Also Published As

Publication number Publication date
AU2001291911A1 (en) 2002-04-08
ES2322432T3 (es) 2009-06-22
US20040101914A1 (en) 2004-05-27
JP5254517B2 (ja) 2013-08-07
FI20002127A0 (fi) 2000-09-27
EP1320756A1 (de) 2003-06-25
JP2004509934A (ja) 2004-04-02
US7872104B2 (en) 2011-01-18
EP1320756B1 (de) 2009-03-11
WO2002027323A1 (en) 2002-04-04
DE60137949D1 (de) 2009-04-23

Similar Documents

Publication Publication Date Title
ATE425460T1 (de) Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs
Mönig et al. Expression of MMP‐2 is associated with progression and lymph node metastasis of gastric carcinoma
Chang et al. Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen
Xing et al. Neuroendocrine cells in human prostate over‐express the anti‐apoptosis protein survivin
Chang et al. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma
Fritzsche et al. ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression
Cho et al. High level of urokinase‐type plasminogen activator is a new prognostic marker in patients with gastric carcinoma
EP1565489A4 (de) Neues raag10-zelloberflächenziel und dieses ziel erkennende antikörperfamilie
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
ATE524196T1 (de) An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
DE69940436D1 (de) Prostata stammzellantigen (psca) und dessen verwendungen
HUP9701717A2 (hu) Eljárás cPSA-meghatározására
DE69937835D1 (de) Antikörper für apoptosemarker und anwendungsverfahren
WO2003024191A3 (en) Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
Strojan et al. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients
ATE412756T1 (de) Verfahren zur krebsdiagnose mittels eines chimärischen toxin
Wang et al. Benign prostatic hyperplasia‐associated prostate‐specific antigen (BPSA) shows unique immunoreactivity with anti‐PSA monoclonal antibodies
AU2007317753A1 (en) Differential gene expression in physiological and pathological angiogenesis
ATE283483T1 (de) Tumorenspezifisches p450 protein
Moul et al. Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen
ATE491727T1 (de) Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen
ATE404676T1 (de) Prostat-spezifisches-antigenformen und verfahren zu ihrer bestimmung
WO2002063048A3 (en) Methods for predicting sensitivity of tumors to arginine deprivation
Bandiera et al. Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response
WO2002023200A3 (en) Human breast cancer biomarkers

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties